{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T02:33:11Z","timestamp":1790044391835,"version":"4.0.1"},"reference-count":170,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T00:00:00Z","timestamp":1635811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T00:00:00Z","timestamp":1635811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1038\/s41575-021-00531-4","type":"journal-article","created":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T07:03:37Z","timestamp":1635836617000},"page":"95-111","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Evolutionary dynamics in Barrett oesophagus: implications for surveillance, risk stratification and therapy"],"prefix":"10.1038","volume":"19","author":[{"given":"Melissa","family":"Schmidt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Hackett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8905-9137","authenticated-orcid":false,"given":"Ann-Marie","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2386-4915","authenticated-orcid":false,"given":"Stuart A. C.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Quante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9582-1597","authenticated-orcid":false,"given":"Trevor A.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,2]]},"reference":[{"key":"531_CR1","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/sj.bjc.6605246","volume":"101","author":"MB Cook","year":"2009","unstructured":"Cook, M. B., Chow, W. H. & Devesa, S. S. Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977\u20132005. Br. J. Cancer 101, 855\u2013859 (2009).","journal-title":"Br. J. Cancer"},{"key":"531_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"531_CR3","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S1470-2045(19)30456-5","volume":"20","author":"M Arnold","year":"2019","unstructured":"Arnold, M. et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995\u20132014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol. 20, 1493\u20131505 (2019).","journal-title":"Lancet Oncol."},{"key":"531_CR4","first-page":"234","volume":"70","author":"E Morgan","year":"2021","unstructured":"Morgan, E. et al. International trends in oesophageal cancer survival by histological subtype between 1995 and 2014. Gut 70, 234\u2013242 (2021).","journal-title":"Gut"},{"key":"531_CR5","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1136\/gutjnl-2020-321600","volume":"69","author":"M Arnold","year":"2020","unstructured":"Arnold, M., Ferlay, J., van Berge Henegouwen, M. I. & Soerjomataram, I. Global burden of oesophageal and gastric cancer by histology and subsite in 2018. Gut 69, 1564\u20131571 (2020).","journal-title":"Gut"},{"key":"531_CR6","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1038\/ajg.2017.155","volume":"112","author":"M Arnold","year":"2017","unstructured":"Arnold, M., Laversanne, M., Brown, L. M., Devesa, S. S. & Bray, F. Predicting the future burden of esophageal cancer by histological subtype: international trends in incidence up to 2030. Am. J. Gastroenterol. 112, 1247\u20131255 (2017). Predictions fitting and extrapolating age\u2013period\u2013cohort models expect the number of new EAC cases to increase rapidly between 2005 and 2030, thereby becoming the predominant type of oesophageal cancer in a growing number of high-income countries.","journal-title":"Am. J. Gastroenterol."},{"key":"531_CR7","doi-asserted-by":"publisher","first-page":"17048","DOI":"10.1038\/nrdp.2017.48","volume":"3","author":"EC Smyth","year":"2017","unstructured":"Smyth, E. C. et al. Oesophageal cancer. Nat. Rev. Dis. Prim. 3, 17048 (2017).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"531_CR8","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1097\/PAS.0000000000000598","volume":"40","author":"BV Naini","year":"2016","unstructured":"Naini, B. V., Souza, R. F. & Odze, R. D. Barrett\u2019s esophagus: a comprehensive and contemporary review for pathologists. Am. J. Surg. Pathol. 40, e45\u2013e66 (2016).","journal-title":"Am. J. Surg. Pathol."},{"key":"531_CR9","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1053\/j.gastro.2010.01.002","volume":"138","author":"SJ Spechler","year":"2010","unstructured":"Spechler, S. J., Fitzgerald, R. C., Prasad, G. A. & Wang, K. K. History, molecular mechanisms, and endoscopic treatment of Barrett\u2019s esophagus. Gastroenterology 138, 854\u2013869 (2010).","journal-title":"Gastroenterology"},{"key":"531_CR10","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1053\/j.gastro.2005.08.053","volume":"129","author":"J Ronkainen","year":"2005","unstructured":"Ronkainen, J. et al. Prevalence of Barrett\u2019s esophagus in the general population: an endoscopic study. Gastroenterology 129, 1825\u20131831 (2005).","journal-title":"Gastroenterology"},{"key":"531_CR11","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1136\/gut.2007.145177","volume":"57","author":"RM Zagari","year":"2008","unstructured":"Zagari, R. M. et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett\u2019s oesophagus in the general population: the Loiano-Monghidoro study. Gut 57, 1354\u20131359 (2008).","journal-title":"Gut"},{"key":"531_CR12","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.gtc.2015.02.001","volume":"44","author":"TM Runge","year":"2015","unstructured":"Runge, T. M., Abrams, J. A. & Shaheen, N. J. Epidemiology of Barrett\u2019s esophagus and esophageal adenocarcinoma. Gastroenterol. Clin. North. Am. 44, 203\u2013231 (2015).","journal-title":"Gastroenterol. Clin. North. Am."},{"key":"531_CR13","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0140-6736(20)31099-0","volume":"396","author":"RC Fitzgerald","year":"2020","unstructured":"Fitzgerald, R. C. et al. Cytosponge-trefoil factor 3 versus usual care to identify Barrett\u2019s oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial. Lancet 396, 333\u2013344 (2020). A multicentre randomized controlled trial showed superior performance of Barrett oesophagus detection in the primary care setting using a novel non-endoscopic Cytosponge-TFF3 device compared with standard care in the primary care setting of patients with gastro-oesophageal reflux.","journal-title":"Lancet"},{"key":"531_CR14","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/S0140-6736(09)60487-6","volume":"373","author":"NJ Shaheen","year":"2009","unstructured":"Shaheen, N. J. & Richter, J. E. Barrett\u2019s oesophagus. Lancet 373, 850\u2013861 (2009).","journal-title":"Lancet"},{"key":"531_CR15","doi-asserted-by":"publisher","first-page":"doaa131","DOI":"10.1093\/dote\/doaa131","volume":"34","author":"N Hamade","year":"2021","unstructured":"Hamade, N. et al. Significant decline in the prevalence of Barrett\u2019s esophagus among patients with gastroesophageal reflux disease. Dis. Esophagus 34, doaa131 (2021).","journal-title":"Dis. Esophagus"},{"key":"531_CR16","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1007\/s10620-018-5192-3","volume":"63","author":"M O\u2019Donovan","year":"2018","unstructured":"O\u2019Donovan, M. & Fitzgerald, R. C. Screening for Barrett\u2019s esophagus: are new high-volume methods feasible? Dig. Dis. Sci. 63, 2105\u20132114 (2018).","journal-title":"Dig. Dis. Sci."},{"key":"531_CR17","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1111\/j.1572-0241.2007.01230.x","volume":"102","author":"R Harrison","year":"2007","unstructured":"Harrison, R. et al. Detection of intestinal metaplasia in Barrett\u2019s esophagus: an observational comparator study suggests the need for a minimum of eight biopsies. Am. J. Gastroenterol. 102, 1154\u20131161 (2007).","journal-title":"Am. J. Gastroenterol."},{"key":"531_CR18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1055\/s-0042-122140","volume":"49","author":"B Weusten","year":"2017","unstructured":"Weusten, B. et al. Endoscopic management of Barrett\u2019s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) position statement. Endoscopy 49, 191\u2013198 (2017).","journal-title":"Endoscopy"},{"key":"531_CR19","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/ajg.2015.322","volume":"111","author":"NJ Shaheen","year":"2016","unstructured":"Shaheen, N. J., Falk, G. W., Iyer, P. G. & Gerson, L. B., American College of Gastroenterology. ACG Clinical Guideline: diagnosis and management of Barrett\u2019s esophagus. Am. J. Gastroenterol. 111, 30\u201350 (2016).","journal-title":"Am. J. Gastroenterol."},{"key":"531_CR20","doi-asserted-by":"publisher","first-page":"356","DOI":"10.5009\/gnl.2014.8.4.356","volume":"8","author":"M di Pietro","year":"2014","unstructured":"di Pietro, M., Alzoubaidi, D. & Fitzgerald, R. C. Barrett\u2019s esophagus and cancer risk: how research advances can impact clinical practice. Gut Liver 8, 356\u2013370 (2014).","journal-title":"Gut Liver"},{"key":"531_CR21","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1111\/j.1572-0241.2000.02002.x","volume":"95","author":"DS Levine","year":"2000","unstructured":"Levine, D. S., Blount, P. L., Rudolph, R. E. & Reid, B. J. Safety of a systematic endoscopic biopsy protocol in patients with Barrett\u2019s esophagus. Am. J. Gastroenterol. 95, 1152\u20131157 (2000).","journal-title":"Am. J. Gastroenterol."},{"key":"531_CR22","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1053\/j.gastro.2006.08.032","volume":"131","author":"P Sharma","year":"2006","unstructured":"Sharma, P. et al. The development and validation of an endoscopic grading system for Barrett\u2019s esophagus: the Prague C & M criteria. Gastroenterology 131, 1392\u20131399 (2006).","journal-title":"Gastroenterology"},{"key":"531_CR23","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1136\/gutjnl-2015-309220","volume":"65","author":"H Pohl","year":"2016","unstructured":"Pohl, H. et al. Length of Barrett\u2019s oesophagus and cancer risk: implications from a large sample of patients with early oesophageal adenocarcinoma. Gut 65, 196\u2013201 (2016).","journal-title":"Gut"},{"key":"531_CR24","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.clinre.2018.06.004","volume":"42","author":"A Antony","year":"2018","unstructured":"Antony, A. et al. Adherence to quality indicators in endoscopic surveillance of Barrett\u2019s esophagus and correlation to dysplasia detection rates. Clin. Res. Hepatol. Gastroenterol. 42, 591\u2013596 (2018).","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"531_CR25","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/ajg.2014.156","volume":"109","author":"RE Verbeek","year":"2014","unstructured":"Verbeek, R. E. et al. Surveillance of Barrett\u2019s esophagus and mortality from esophageal adenocarcinoma: a population-based cohort study. Am. J. Gastroenterol. 109, 1215\u20131222 (2014).","journal-title":"Am. J. Gastroenterol."},{"key":"531_CR26","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1080\/00365521.2019.1641740","volume":"54","author":"D Holmberg","year":"2019","unstructured":"Holmberg, D., Ness-Jensen, E., Mattsson, F. & Lagergren, J. Adherence to clinical guidelines for Barrett\u2019s esophagus. Scand. J. Gastroenterol. 54, 945\u2013952 (2019).","journal-title":"Scand. J. Gastroenterol."},{"key":"531_CR27","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.gie.2007.08.039","volume":"67","author":"FP Peters","year":"2008","unstructured":"Peters, F. P. et al. Histologic evaluation of resection specimens obtained at 293 endoscopic resections in Barrett\u2019s esophagus. Gastrointest. Endosc. 67, 604\u2013609 (2008).","journal-title":"Gastrointest. Endosc."},{"key":"531_CR28","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1136\/gut.47.2.251","volume":"47","author":"RJ Schlemper","year":"2000","unstructured":"Schlemper, R. J. et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 47, 251\u2013255 (2000).","journal-title":"Gut"},{"key":"531_CR29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1136\/gutjnl-2013-305372","volume":"63","author":"RC Fitzgerald","year":"2014","unstructured":"Fitzgerald, R. C. et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett\u2019s oesophagus. Gut 63, 7\u201342 (2014).","journal-title":"Gut"},{"key":"531_CR30","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1053\/j.gastro.2016.10.041","volume":"152","author":"P Vennalaganti","year":"2017","unstructured":"Vennalaganti, P. et al. Discordance among pathologists in the United States and Europe in diagnosis of low-grade dysplasia for patients with Barrett\u2019s esophagus. Gastroenterology 152, 564\u2013570.e4 (2017).","journal-title":"Gastroenterology"},{"key":"531_CR31","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1097\/PAS.0000000000000988","volume":"42","author":"MA Salomao","year":"2018","unstructured":"Salomao, M. A., Lam-Himlin, D. & Pai, R. K. Substantial interobserver agreement in the diagnosis of dysplasia in Barrett esophagus upon review of a patient\u2019s entire set of biopsies. Am. J. Surg. Pathol. 42, 376\u2013381 (2018).","journal-title":"Am. J. Surg. Pathol."},{"key":"531_CR32","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1053\/hupa.2001.23510","volume":"32","author":"E Montgomery","year":"2001","unstructured":"Montgomery, E. et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum. Pathol. 32, 368\u2013378 (2001).","journal-title":"Hum. Pathol."},{"key":"531_CR33","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1053\/j.gastro.2011.01.031","volume":"140","author":"SJ Spechler","year":"2011","unstructured":"Spechler, S. J., Sharma, P., Souza, R. F., Inadomi, J. M. & Shaheen, N. J. American Gastroenterological Association medical position statement on the management of Barrett\u2019s esophagus. Gastroenterology 140, 1084\u20131091 (2011).","journal-title":"Gastroenterology"},{"key":"531_CR34","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1056\/NEJMoa1103042","volume":"365","author":"F Hvid-Jensen","year":"2011","unstructured":"Hvid-Jensen, F., Pedersen, L., Drewes, A. M., S\u00f8rensen, H. T. & Funch-Jensen, P. Incidence of adenocarcinoma among patients with Barrett\u2019s esophagus. N. Engl. J. Med. 365, 1375\u20131383 (2011).","journal-title":"N. Engl. J. Med."},{"key":"531_CR35","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S0140-6736(18)31618-0","volume":"392","author":"F Hvid-Jensen","year":"2018","unstructured":"Hvid-Jensen, F. & Drewes, A. M. Should aspirin and PPIs be recommended for patients with Barrett\u2019s oesophagus? Lancet 392, 362\u2013364 (2018).","journal-title":"Lancet"},{"issue":"Suppl. 6","key":"531_CR36","doi-asserted-by":"publisher","first-page":"s78","DOI":"10.7861\/clinmedicine.14-6-s78","volume":"14","author":"S Zeki","year":"2014","unstructured":"Zeki, S. & Fitzgerald, R. C. Targeting care in Barrett\u2019s oesophagus. Clin. Med. 14 (Suppl. 6), s78\u2013s83 (2014).","journal-title":"Clin. Med."},{"key":"531_CR37","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1007\/s10620-018-5241-y","volume":"63","author":"TN Wenker","year":"2018","unstructured":"Wenker, T. N., Tan, M. C., Liu, Y., El-Serag, H. B. & Thrift, A. P. Prior diagnosis of Barrett\u2019s esophagus is infrequent, but associated with improved esophageal adenocarcinoma survival. Dig. Dis. Sci. 63, 3112\u20133119 (2018).","journal-title":"Dig. Dis. Sci."},{"key":"531_CR38","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1053\/j.gastro.2015.11.040","volume":"150","author":"K Visrodia","year":"2016","unstructured":"Visrodia, K. et al. Magnitude of missed esophageal adenocarcinoma after Barrett\u2019s esophagus diagnosis: a systematic review and meta-analysis. Gastroenterology 150, 599\u2013607.e7 (2016).","journal-title":"Gastroenterology"},{"key":"531_CR39","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1126\/science.959840","volume":"194","author":"PC Nowell","year":"1976","unstructured":"Nowell, P. C. The clonal evolution of tumor cell populations. Science 194, 23\u201328 (1976).","journal-title":"Science"},{"key":"531_CR40","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/nature10762","volume":"481","author":"M Greaves","year":"2012","unstructured":"Greaves, M. & Maley, C. C. Clonal evolution in cancer. Nature 481, 306\u2013313 (2012). This Review explains fundamental principles of clonal evolution in cancer such as genetic diversification, genetic drivers, the clonal architecture, clonal dynamics and the influence of the cancer ecosystem.","journal-title":"Nature"},{"key":"531_CR41","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.cell.2012.04.023","volume":"149","author":"S Nik-Zainal","year":"2012","unstructured":"Nik-Zainal, S. et al. The life history of 21 breast cancers. Cell 149, 994\u20131007 (2012).","journal-title":"Cell"},{"key":"531_CR42","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1113205","volume":"366","author":"M Gerlinger","year":"2012","unstructured":"Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883\u2013892 (2012).","journal-title":"N. Engl. J. Med."},{"key":"531_CR43","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1073\/pnas.1219747110","volume":"110","author":"A Sottoriva","year":"2013","unstructured":"Sottoriva, A. et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc. Natl Acad. Sci. USA 110, 4009\u20134014 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"531_CR44","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1126\/science.1253462","volume":"346","author":"EC de Bruin","year":"2014","unstructured":"de Bruin, E. C. et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346, 251\u2013256 (2014).","journal-title":"Science"},{"key":"531_CR45","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nature14347","volume":"520","author":"G Gundem","year":"2015","unstructured":"Gundem, G. et al. The evolutionary history of lethal metastatic prostate cancer. Nature 520, 353\u2013357 (2015).","journal-title":"Nature"},{"key":"531_CR46","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.cell.2013.01.019","volume":"152","author":"DA Landau","year":"2013","unstructured":"Landau, D. A. et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152, 714\u2013726 (2013).","journal-title":"Cell"},{"key":"531_CR47","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/nrc2013","volume":"6","author":"LMF Merlo","year":"2006","unstructured":"Merlo, L. M. F., Pepper, J. W., Reid, B. J. & Maley, C. C. Cancer as an evolutionary and ecological process. Nat. Rev. Cancer 6, 924\u2013935 (2006).","journal-title":"Nat. Rev. Cancer"},{"key":"531_CR48","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00535-017-1342-1","volume":"52","author":"RF Souza","year":"2017","unstructured":"Souza, R. F. Reflux esophagitis and its role in the pathogenesis of Barrett\u2019s metaplasia. J. Gastroenterol. 52, 767\u2013776 (2017).","journal-title":"J. Gastroenterol."},{"key":"531_CR49","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/j.1365-2036.2011.04709.x","volume":"34","author":"KR McQuaid","year":"2011","unstructured":"McQuaid, K. R., Laine, L., Fennerty, M. B., Souza, R. & Spechler, S. J. Systematic review: the role of bile acids in the pathogenesis of gastro-oesophageal reflux disease and related neoplasia. Aliment. Pharmacol. Ther. 34, 146\u2013165 (2011).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"531_CR50","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1053\/j.gastro.2019.03.072","volume":"157","author":"J Que","year":"2019","unstructured":"Que, J., Garman, K. S., Souza, R. F. & Spechler, S. J. Pathogenesis and cells of origin of Barrett\u2019s esophagus. Gastroenterology 157, 349\u2013364.e1 (2019).","journal-title":"Gastroenterology"},{"key":"531_CR51","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/nature24269","volume":"550","author":"M Jiang","year":"2017","unstructured":"Jiang, M. et al. Transitional basal cells at the squamous-columnar junction generate Barrett\u2019s oesophagus. Nature 550, 529\u2013533 (2017).","journal-title":"Nature"},{"key":"531_CR52","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1136\/gut.2007.143339","volume":"57","author":"SJ Leedham","year":"2008","unstructured":"Leedham, S. J. et al. Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett\u2019s oesophagus. Gut 57, 1041\u20131048 (2008).","journal-title":"Gut"},{"key":"531_CR53","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jcmgh.2017.07.005","volume":"4","author":"RJ von Furstenberg","year":"2017","unstructured":"von Furstenberg, R. J. et al. Porcine esophageal submucosal gland culture model shows capacity for proliferation and differentiation. Cell Mol. Gastroenterol. Hepatol. 4, 385\u2013404 (2017).","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"531_CR54","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.cell.2011.05.026","volume":"145","author":"X Wang","year":"2011","unstructured":"Wang, X. et al. Residual embryonic cells as precursors of a Barrett\u2019s-like metaplasia. Cell 145, 1023\u20131035 (2011).","journal-title":"Cell"},{"key":"531_CR55","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1126\/science.abd1449","volume":"373","author":"K Nowicki-Osuch","year":"2021","unstructured":"Nowicki-Osuch, K. et al. Molecular phenotyping reveals the identity of Barrett\u2019s esophagus and its malignant transition. Science 373, 760\u2013767 (2021).","journal-title":"Science"},{"key":"531_CR56","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41572-019-0086-z","volume":"5","author":"Y Peters","year":"2019","unstructured":"Peters, Y. et al. Barrett oesophagus. Nat. Rev. Dis. Prim. 5, 35 (2019).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"531_CR57","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1093\/jnci\/91.24.2087","volume":"91","author":"PC Galipeau","year":"1999","unstructured":"Galipeau, P. C., Prevo, L. J., Sanchez, C. A., Longton, G. M. & Reid, B. J. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett\u2019s) tissue. J. Natl Cancer Inst. 91, 2087\u20132095 (1999).","journal-title":"J. Natl Cancer Inst."},{"key":"531_CR58","first-page":"8284","volume":"61","author":"DJ Wong","year":"2001","unstructured":"Wong, D. J. et al. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett\u2019s metaplastic epithelium. Cancer Res. 61, 8284\u20138289 (2001).","journal-title":"Cancer Res."},{"key":"531_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12158","volume":"7","author":"P Martinez","year":"2016","unstructured":"Martinez, P. et al. Dynamic clonal equilibrium and predetermined cancer risk in Barrett\u2019s oesophagus. Nat. Commun. 7, 12158 (2016). A longitudinal single-cell fluorescent in situ hybridization analysis of non-dysplastic Barrett oesophagus biopsy samples, including 300 non-progressing and 20 progressing Barrett oesophagus lesions, showing that clones exist in a dynamic equilibrium with relatively stable levels of genetic diversity over time, whereby clonal expansions are rare events.","journal-title":"Nat. Commun."},{"key":"531_CR60","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1158\/1940-6207.CAPR-15-0130","volume":"8","author":"X Li","year":"2015","unstructured":"Li, X. et al. Assessment of esophageal adenocarcinoma risk using somatic chromosome alterations in longitudinal samples in Barrett\u2019s esophagus. Cancer Prev. Res. 8, 845\u2013856 (2015). A multi-region SNP array analysis of CNAs in 248 patients with Barrett oesophagus over space and time showing that non-progressing Barrett oesophagus typically harbours a low burden of large-scale CNAs that remain low over time, whereas progressing Barrett oesophagus develops high levels of CNAs.","journal-title":"Cancer Prev. Res."},{"key":"531_CR61","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/ng1768","volume":"38","author":"CC Maley","year":"2006","unstructured":"Maley, C. C. et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat. Genet. 38, 468\u2013473 (2006). A fluorescent in situ hybridization study including 268 patients with non-progressing Barrett oesophagus and 37 patients with progressing Barrett oesophagus identifies genetic clonal diversity as a predictor of progression to EAC in patients with Barrett oesophagus.","journal-title":"Nat. Genet."},{"key":"531_CR62","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1038\/ng.3357","volume":"47","author":"CS Ross-Innes","year":"2015","unstructured":"Ross-Innes, C. S. et al. Whole-genome sequencing provides new insights into the clonal architecture of Barrett\u2019s esophagus and esophageal adenocarcinoma. Nat. Genet. 47, 1038\u20131046 (2015). Whole-genome sequencing on 23 paired Barrett oesophagus and EAC samples and one in-depth Barrett oesophagus case sampled over time and space reveals the presence of mutations and copy number changes in non-dysplastic Barrett prior to the phenotypic evolution of the clonally related HGD descendent, questioning the adequacy of dysplasia as a biomarker for cancer risk.","journal-title":"Nat. Genet."},{"key":"531_CR63","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q","volume":"6","author":"DP Slaughter","year":"1953","unstructured":"Slaughter, D. P., Southwick, H. W. & Smejkal, W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 6, 963\u2013968 (1953).","journal-title":"Cancer"},{"key":"531_CR64","first-page":"1727","volume":"63","author":"BJM Braakhuis","year":"2003","unstructured":"Braakhuis, B. J. M., Tabor, M. P., Kummer, J. A., Leemans, C. R. & Brakenhoff, R. H. A genetic explanation of Slaughter\u2019s concept of field cancerization: evidence and clinical implications. Cancer Res. 63, 1727\u20131730 (2003).","journal-title":"Cancer Res."},{"key":"531_CR65","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1053\/j.gastro.2011.12.004","volume":"142","author":"S Galandiuk","year":"2012","unstructured":"Galandiuk, S. et al. Field cancerization in the intestinal epithelium of patients with Crohn\u2019s ileocolitis. Gastroenterology 142, 855\u2013864.e8 (2012).","journal-title":"Gastroenterology"},{"key":"531_CR66","first-page":"5021","volume":"60","author":"CA Eads","year":"2000","unstructured":"Eads, C. A. et al. Fields of aberrant CpG island hypermethylation in Barrett\u2019s esophagus and associated adenocarcinoma. Cancer Res. 60, 5021\u20135026 (2000).","journal-title":"Cancer Res."},{"key":"531_CR67","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1158\/1940-6207.CAPR-09-0265","volume":"3","author":"J Gu","year":"2010","unstructured":"Gu, J. et al. Genome-wide catalogue of chromosomal aberrations in Barrett\u2019s esophagus and esophageal adenocarcinoma: a high-density single nucleotide polymorphism array analysis. Cancer Prev. Res. 3, 1176\u20131186 (2010).","journal-title":"Cancer Prev. Res."},{"issue":"Suppl. 2","key":"531_CR68","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/00008469-199612002-00009","volume":"5","author":"BJ Reid","year":"1996","unstructured":"Reid, B. J. et al. Barrett\u2019s esophagus: ordering the events that lead to cancer. Eur. J. Cancer Prev. 5 (Suppl. 2), 57\u201365 (1996).","journal-title":"Eur. J. Cancer Prev."},{"key":"531_CR69","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1158\/1940-6207.CAPR-13-0289","volume":"7","author":"X Li","year":"2014","unstructured":"Li, X. et al. Temporal and spatial evolution of somatic chromosomal alterations: a case-cohort study of Barrett\u2019s esophagus. Cancer Prev. Res. 7, 114\u2013127 (2014). A large longitudinal study that examines multi-region CNA profiles of 79 patients with Barrett oesophagus that progressed to EAC and 169 patients with Barrett oesophagus that did not progress and showed that progressing Barrett oesophagus has more CNAs than non-progressing Barrett oesophagus and that progressors display a sudden sharp increase in genetic alterations 2\u20134 years before cancer detection.","journal-title":"Cancer Prev. Res."},{"key":"531_CR70","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.canlet.2004.06.025","volume":"217","author":"LJ Hardie","year":"2005","unstructured":"Hardie, L. J. et al. p16 expression in Barrett\u2019s esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations. Cancer Lett. 217, 221\u2013230 (2005).","journal-title":"Cancer Lett."},{"key":"531_CR71","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1053\/gast.2002.32370","volume":"122","author":"Y-S Bian","year":"2002","unstructured":"Bian, Y.-S., Osterheld, M.-C., Fontolliet, C., Bosman, F. T. & Benhattar, J. p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett\u2019s esophagus. Gastroenterology 122, 1113\u20131121 (2002).","journal-title":"Gastroenterology"},{"key":"531_CR72","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1038\/ng.3343","volume":"47","author":"MD Stachler","year":"2015","unstructured":"Stachler, M. D. et al. Paired exome analysis of Barrett\u2019s esophagus and adenocarcinoma. Nat. Genet. 47, 1047\u20131055 (2015). A paired whole-exome study of Barrett oesophagus and EAC suggesting that many EACs emerge through TP53 mutation with subsequent genome doubling, followed by the acquisition of oncogenic amplifications.","journal-title":"Nat. Genet."},{"key":"531_CR73","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/ng.3013","volume":"46","author":"JMJ Weaver","year":"2014","unstructured":"Weaver, J. M. J. et al. Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nat. Genet. 46, 837\u2013843 (2014). A whole-genome sequencing study including EAC, high-grade dysplasia and non-dysplastic Barrett oesophagus shows that only mutations in TP53 and SMAD4 occur in a stage-specific manner, whereas the majority of recurrently mutated genes in EAC are also mutated in non-dysplastic Barrett oesophagus and might therefore occur early in Barrett development.","journal-title":"Nat. Genet."},{"key":"531_CR74","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/ng.2591","volume":"45","author":"AM Dulak","year":"2013","unstructured":"Dulak, A. M. et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat. Genet. 45, 478\u2013486 (2013).","journal-title":"Nat. Genet."},{"key":"531_CR75","doi-asserted-by":"publisher","first-page":"7081","DOI":"10.1073\/pnas.93.14.7081","volume":"93","author":"PC Galipeau","year":"1996","unstructured":"Galipeau, P. C. et al. 17p (p53) allelic losses, 4N (G2\/tetraploid) populations, and progression to aneuploidy in Barrett\u2019s esophagus. Proc. Natl Acad. Sci. USA 93, 7081\u20137084 (1996).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"531_CR76","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1111\/j.1572-0241.2001.04236.x","volume":"96","author":"BJ Reid","year":"2001","unstructured":"Reid, B. J. et al. Predictors of progression in Barrett\u2019s esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am. J. Gastroenterol. 96, 2839\u20132848 (2001).","journal-title":"Am. J. Gastroenterol."},{"key":"531_CR77","doi-asserted-by":"publisher","first-page":"7629","DOI":"10.1158\/0008-5472.CAN-04-1738","volume":"64","author":"CC Maley","year":"2004","unstructured":"Maley, C. C. et al. The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma. Cancer Res. 64, 7629\u20137633 (2004).","journal-title":"Cancer Res."},{"key":"531_CR78","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1038\/s41591-020-1033-y","volume":"26","author":"S Killcoyne","year":"2020","unstructured":"Killcoyne, S. et al. Genomic copy number predicts esophageal cancer years before transformation. Nat. Med. 26, 1726\u20131732 (2020). Using shallow whole-genome sequencing of 777 Barrett oesophagus biopsy samples from a retrospective cohort of 88 patients undergoing Barrett oesophagus surveillance, a risk stratification model based on CNA profile complexity was able to identify 50% of patients at high risk \u22658 years before clinical progression and showed improving detection rates to 78% and 85% at 2 years and 1 year prior, respectively.","journal-title":"Nat. Med."},{"key":"531_CR79","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1053\/j.gastro.2017.09.046","volume":"154","author":"M Quante","year":"2018","unstructured":"Quante, M., Graham, T. A. & Jansen, M. Insights into the pathophysiology of esophageal adenocarcinoma. Gastroenterology 154, 406\u2013420 (2018).","journal-title":"Gastroenterology"},{"key":"531_CR80","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1053\/j.gastro.2007.11.035","volume":"134","author":"SAC McDonald","year":"2008","unstructured":"McDonald, S. A. C. et al. Mechanisms of field cancerization in the human stomach: the expansion and spread of mutated gastric stem cells. Gastroenterology 134, 500\u2013510 (2008).","journal-title":"Gastroenterology"},{"key":"531_CR81","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s11605-011-1776-3","volume":"16","author":"D Theodorou","year":"2012","unstructured":"Theodorou, D. et al. Intraluminal pH and goblet cell density in Barrett\u2019s esophagus. J. Gastrointest. Surg. 16, 469\u2013474 (2012).","journal-title":"J. Gastrointest. Surg."},{"key":"531_CR82","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ccr.2011.12.004","volume":"21","author":"M Quante","year":"2012","unstructured":"Quante, M. et al. Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia. Cancer Cell 21, 36\u201351 (2012). In a transgenic mouse model of Barrett oesophagus, oesophageal overexpression of IL-1\u03b2 led to oesophagitis, Barrett-like metaplasia and EAC, which could be accelerated by exposure to bile acids and nitrosamines.","journal-title":"Cancer Cell"},{"key":"531_CR83","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/j.1572-0241.2004.04057.x","volume":"99","author":"JM O\u2019Riordan","year":"2004","unstructured":"O\u2019Riordan, J. M. et al. Factors influencing the development of Barrett\u2019s epithelium in the esophageal remnant postesophagectomy. Am. J. Gastroenterol. 99, 205\u2013211 (2004).","journal-title":"Am. J. Gastroenterol."},{"key":"531_CR84","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1136\/gutjnl-2015-310748","volume":"65","author":"DL Lavery","year":"2016","unstructured":"Lavery, D. L. et al. Evolution of oesophageal adenocarcinoma from metaplastic columnar epithelium without goblet cells in Barrett\u2019s oesophagus. Gut 65, 907\u2013913 (2016).","journal-title":"Gut"},{"key":"531_CR85","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/path.4211","volume":"231","author":"S Khan","year":"2013","unstructured":"Khan, S. et al. Crypt dysplasia in Barrett\u2019s oesophagus shows clonal identity between crypt and surface cells. J. Pathol. 231, 98\u2013104 (2013).","journal-title":"J. Pathol."},{"key":"531_CR86","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1056\/NEJM198809013190901","volume":"319","author":"B Vogelstein","year":"1988","unstructured":"Vogelstein, B. et al. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 319, 525\u2013532 (1988).","journal-title":"N. Engl. J. Med."},{"key":"531_CR87","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/path.4821","volume":"241","author":"TA Graham","year":"2017","unstructured":"Graham, T. A. & Sottoriva, A. Measuring cancer evolution from the genome. J. Pathol. 241, 183\u2013191 (2017).","journal-title":"J. Pathol."},{"key":"531_CR88","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1126\/science.276.5311.337c","volume":"276","author":"N Eldredge","year":"1997","unstructured":"Eldredge, N. & Gould, S. J. On punctuated equilibria. Science 276, 338\u2013341 (1997).","journal-title":"Science"},{"key":"531_CR89","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-019-0476-9","volume":"12","author":"F Newell","year":"2019","unstructured":"Newell, F. et al. Complex structural rearrangements are present in high-grade dysplastic Barrett\u2019s oesophagus samples. BMC Med. Genomics 12, 31 (2019).","journal-title":"BMC Med. Genomics"},{"key":"531_CR90","unstructured":"Goldschmidt, R. The Material Basis of Evolution (Yale Univ. Press, 1940)."},{"key":"531_CR91","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nbt.2203","volume":"30","author":"SL Carter","year":"2012","unstructured":"Carter, S. L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413\u2013421 (2012).","journal-title":"Nat. Biotechnol."},{"key":"531_CR92","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6224","volume":"5","author":"K Nones","year":"2014","unstructured":"Nones, K. et al. Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis. Nat. Commun. 5, 5224 (2014).","journal-title":"Nat. Commun."},{"key":"531_CR93","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cell.2010.11.055","volume":"144","author":"PJ Stephens","year":"2011","unstructured":"Stephens, P. J. et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144, 27\u201340 (2011).","journal-title":"Cell"},{"key":"531_CR94","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nature19823","volume":"538","author":"F Notta","year":"2016","unstructured":"Notta, F. et al. A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. Nature 538, 378\u2013382 (2016).","journal-title":"Nature"},{"key":"531_CR95","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1101\/gr.143677.112","volume":"23","author":"A Malhotra","year":"2013","unstructured":"Malhotra, A. et al. Breakpoint profiling of 64 cancer genomes reveals numerous complex rearrangements spawned by homology-independent mechanisms. Genome Res. 23, 762\u2013776 (2013).","journal-title":"Genome Res."},{"key":"531_CR96","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.cell.2011.12.013","volume":"148","author":"T Rausch","year":"2012","unstructured":"Rausch, T. et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 148, 59\u201371 (2012).","journal-title":"Cell"},{"key":"531_CR97","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-15-579","volume":"15","author":"E Przybytkowski","year":"2014","unstructured":"Przybytkowski, E. et al. Chromosome-breakage genomic instability and chromothripsis in breast cancer. BMC Genomics 15, 579 (2014).","journal-title":"BMC Genomics"},{"key":"531_CR98","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1158\/1055-9965.EPI-05-0837","volume":"15","author":"JC Finley","year":"2006","unstructured":"Finley, J. C. et al. Chromosomal instability in Barrett\u2019s esophagus is related to telomere shortening. Cancer Epidemiol. Biomark. Prev. 15, 1451\u20131457 (2006).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"531_CR99","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1093\/jnci\/djq289","volume":"102","author":"MB Cook","year":"2010","unstructured":"Cook, M. B. et al. Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium. J. Natl Cancer Inst. 102, 1344\u20131353 (2010).","journal-title":"J. Natl Cancer Inst."},{"key":"531_CR100","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1053\/j.gastro.2011.10.034","volume":"142","author":"HG Coleman","year":"2012","unstructured":"Coleman, H. G. et al. Tobacco smoking increases the risk of high-grade dysplasia and cancer among patients with Barrett\u2019s esophagus. Gastroenterology 142, 233\u2013240 (2012).","journal-title":"Gastroenterology"},{"key":"531_CR101","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1158\/1055-9965.EPI-04-0509","volume":"14","author":"JR Olliver","year":"2005","unstructured":"Olliver, J. R. et al. Risk factors, DNA damage, and disease progression in Barrett\u2019s esophagus. Cancer Epidemiol. Biomark. Prev. 14, 620\u2013625 (2005).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"531_CR102","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-016-0273-7","volume":"8","author":"AM Kaz","year":"2016","unstructured":"Kaz, A. M. et al. Global DNA methylation patterns in Barrett\u2019s esophagus, dysplastic Barrett\u2019s, and esophageal adenocarcinoma are associated with BMI, gender, and tobacco use. Clin. Epigenetics 8, 111 (2016).","journal-title":"Clin. Epigenetics"},{"key":"531_CR103","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1007\/BF02071391","volume":"41","author":"SC Kadakia","year":"1996","unstructured":"Kadakia, S. C., De La Baume, H. R. & Shaffer, R. T. Effects of transdermal nicotine on lower esophageal sphincter and esophageal motility. Dig. Dis. Sci. 41, 2130\u20132134 (1996).","journal-title":"Dig. Dis. Sci."},{"key":"531_CR104","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-020427","volume":"8","author":"T Nieto","year":"2018","unstructured":"Nieto, T. et al. A systematic review of epigenetic biomarkers in progression from non-dysplastic Barrett\u2019s oesophagus to oesophageal adenocarcinoma. BMJ Open 8, e020427 (2018).","journal-title":"BMJ Open"},{"key":"531_CR105","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","volume":"100","author":"D Hanahan","year":"2000","unstructured":"Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57\u201370 (2000).","journal-title":"Cell"},{"key":"531_CR106","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nri.2017.142","volume":"18","author":"K Taniguchi","year":"2018","unstructured":"Taniguchi, K. & Karin, M. NF-\u03baB, inflammation, immunity and cancer: coming of age. Nat. Rev. Immunol. 18, 309\u2013324 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"531_CR107","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.cgh.2013.12.014","volume":"12","author":"AP Thrift","year":"2014","unstructured":"Thrift, A. P., Garcia, J. M. & El-Serag, H. B. A multibiomarker risk score helps predict risk for Barrett\u2019s esophagus. Clin. Gastroenterol. Hepatol. 12, 1267\u20131271 (2014).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"531_CR108","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1056\/NEJM199903183401101","volume":"340","author":"J Lagergren","year":"1999","unstructured":"Lagergren, J., Bergstr\u00f6m, R., Lindgren, A. & Nyr\u00e9n, O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N. Engl. J. Med. 340, 825\u2013831 (1999).","journal-title":"N. Engl. J. Med."},{"key":"531_CR109","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1158\/1940-6207.CAPR-19-0474","volume":"13","author":"M Schmidt","year":"2020","unstructured":"Schmidt, M. et al. Epidemiologic risk factors in a comparison of a Barrett Esophagus Registry (BarrettNET) and a case-control population in Germany. Cancer Prev. Res. 13, 377\u2013384 (2020).","journal-title":"Cancer Prev. Res."},{"key":"531_CR110","first-page":"3620","volume":"57","author":"J Parsonnet","year":"1997","unstructured":"Parsonnet, J. Molecular mechanisms for inflammation-promoted pathogenesis of cancer \u2014 The Sixteenth International Symposium of the Sapporo Cancer Seminar. Cancer Res. 57, 3620\u20133624 (1997).","journal-title":"Cancer Res."},{"key":"531_CR111","doi-asserted-by":"publisher","first-page":"G411","DOI":"10.1152\/ajpgi.00373.2007","volume":"294","author":"LA Feagins","year":"2008","unstructured":"Feagins, L. A. et al. Mechanisms of oxidant production in esophageal squamous cell and Barrett\u2019s cell lines. Am. J. Physiol. Gastrointest. Liver Physiol. 294, G411\u2013G417 (2008).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"531_CR112","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/ng.3659","volume":"48","author":"M Secrier","year":"2016","unstructured":"Secrier, M. et al. Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nat. Genet. 48, 1131\u20131141 (2016).","journal-title":"Nat. Genet."},{"key":"531_CR113","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1136\/gut.50.4.451","volume":"50","author":"RC Fitzgerald","year":"2002","unstructured":"Fitzgerald, R. C. et al. Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants. Gut 50, 451\u2013459 (2002).","journal-title":"Gut"},{"key":"531_CR114","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1136\/gut.51.3.316","volume":"51","author":"RC Fitzgerald","year":"2002","unstructured":"Fitzgerald, R. C. et al. Inflammatory gradient in Barrett\u2019s oesophagus: implications for disease complications. Gut 51, 316\u2013322 (2002). This article shows that specific cytokine responses with pro-inflammatory IL-8 and IL-1\u03b2 expression might contribute to the local inflammatory microenvironment in Barrett oesophagus.","journal-title":"Gut"},{"key":"531_CR115","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.canlet.2015.10.019","volume":"370","author":"ME Kavanagh","year":"2016","unstructured":"Kavanagh, M. E. et al. Impact of the inflammatory microenvironment on T-cell phenotype in the progression from reflux oesophagitis to Barrett oesophagus and oesophageal adenocarcinoma. Cancer Lett. 370, 117\u2013124 (2016).","journal-title":"Cancer Lett."},{"key":"531_CR116","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1471-230X-4-18","volume":"4","author":"HC Wolfsen","year":"2004","unstructured":"Wolfsen, H. C., Hemminger, L. L. & DeVault, K. R. Recurrent Barrett\u2019s esophagus and adenocarcinoma after esophagectomy. BMC Gastroenterol. 4, 18 (2004).","journal-title":"BMC Gastroenterol."},{"key":"531_CR117","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1097\/00000658-200203000-00005","volume":"235","author":"S Oberg","year":"2002","unstructured":"Oberg, S., Johansson, J., Wenner, J. & Walther, B. Metaplastic columnar mucosa in the cervical esophagus after esophagectomy. Ann. Surg. 235, 338\u2013345 (2002).","journal-title":"Ann. Surg."},{"key":"531_CR118","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/nrc3610","volume":"13","author":"RF Schwabe","year":"2013","unstructured":"Schwabe, R. F. & Jobin, C. The microbiome and cancer. Nat. Rev. Cancer 13, 800\u2013812 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"531_CR119","doi-asserted-by":"publisher","first-page":"17008","DOI":"10.1038\/nmicrobiol.2017.8","volume":"2","author":"MCB Tsilimigras","year":"2017","unstructured":"Tsilimigras, M. C. B., Fodor, A. & Jobin, C. Carcinogenesis and therapeutics: the microbiota perspective. Nat. Microbiol. 2, 17008 (2017).","journal-title":"Nat. Microbiol."},{"key":"531_CR120","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1053\/j.gastro.2009.04.046","volume":"137","author":"L Yang","year":"2009","unstructured":"Yang, L. et al. Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. Gastroenterology 137, 588\u2013597 (2009).","journal-title":"Gastroenterology"},{"key":"531_CR121","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S2468-1253(16)30086-3","volume":"2","author":"DRF Elliott","year":"2017","unstructured":"Elliott, D. R. F., Walker, A. W., O\u2019Donovan, M., Parkhill, J. & Fitzgerald, R. C. A non-endoscopic device to sample the oesophageal microbiota: a case-control study. Lancet Gastroenterol. Hepatol. 2, 32\u201342 (2017).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"531_CR122","doi-asserted-by":"publisher","first-page":"5574","DOI":"10.1158\/1078-0432.CCR-16-1786","volume":"22","author":"K Yamamura","year":"2016","unstructured":"Yamamura, K. et al. Human microbiome fusobacterium nucleatum in esophageal cancer tissue is associated with prognosis. Clin. Cancer Res. 22, 5574\u20135581 (2016).","journal-title":"Clin. Cancer Res."},{"key":"531_CR123","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.chom.2013.07.007","volume":"14","author":"AD Kostic","year":"2013","unstructured":"Kostic, A. D. et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 14, 207\u2013215 (2013).","journal-title":"Cell Host Microbe"},{"key":"531_CR124","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0053653","volume":"8","author":"AN McCoy","year":"2013","unstructured":"McCoy, A. N. et al. Fusobacterium is associated with colorectal adenomas. PLoS ONE 8, e53653 (2013).","journal-title":"PLoS ONE"},{"key":"531_CR125","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1101\/gr.126516.111","volume":"22","author":"M Castellarin","year":"2012","unstructured":"Castellarin, M. et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 22, 299\u2013306 (2012).","journal-title":"Genome Res."},{"key":"531_CR126","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S0140-6736(18)31388-6","volume":"392","author":"JAZ Jankowski","year":"2018","unstructured":"Jankowski, J. A. Z. et al. Esomeprazole and aspirin in Barrett\u2019s oesophagus (AspECT): a randomised factorial trial. Lancet 392, 400\u2013408 (2018). A randomized controlled trial comparing permutations of low-dose and high-dose PPIs with or without aspirin as a chemopreventive strategy in patients with Barrett oesophagus shows a statistically significant benefit of high-dose over low-dose PPIs, which could be enhanced with use of aspirin with high-dose PPIs.","journal-title":"Lancet"},{"key":"531_CR127","volume":"8","author":"M Jovani","year":"2017","unstructured":"Jovani, M. et al. Aspirin use is associated with lower risk of Barrett\u2019s esophagus in women. Clin. Transl. Gastroenterol. 8, e131 (2017).","journal-title":"Clin. Transl. Gastroenterol."},{"key":"531_CR128","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040067","volume":"4","author":"PC Galipeau","year":"2007","unstructured":"Galipeau, P. C. et al. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med. 4, e67 (2007).","journal-title":"PLoS Med."},{"key":"531_CR129","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(10)62110-1","volume":"377","author":"PM Rothwell","year":"2011","unstructured":"Rothwell, P. M. et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377, 31\u201341 (2011).","journal-title":"Lancet"},{"key":"531_CR130","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1056\/NEJMoa021735","volume":"348","author":"JA Baron","year":"2003","unstructured":"Baron, J. A. et al. A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med. 348, 891\u2013899 (2003).","journal-title":"N. Engl. J. Med."},{"key":"531_CR131","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/S0140-6736(07)60747-8","volume":"369","author":"E Flossmann","year":"2007","unstructured":"Flossmann, E. & Rothwell, P. M. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369, 1603\u20131613 (2007).","journal-title":"Lancet"},{"key":"531_CR132","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S1470-2045(12)70112-2","volume":"13","author":"AM Algra","year":"2012","unstructured":"Algra, A. M. & Rothwell, P. M. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 13, 518\u2013527 (2012).","journal-title":"Lancet Oncol."},{"key":"531_CR133","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1053\/j.gastro.2019.06.047","volume":"158","author":"BW Katona","year":"2020","unstructured":"Katona, B. W. & Weiss, J. M. Chemoprevention of colorectal cancer. Gastroenterology 158, 368\u2013388 (2020).","journal-title":"Gastroenterology"},{"key":"531_CR134","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1159\/000341498","volume":"29","author":"SL Picardo","year":"2012","unstructured":"Picardo, S. L., Maher, S. G., O\u2019Sullivan, J. N. & Reynolds, J. V. Barrett\u2019s to oesophageal cancer sequence: a model of inflammatory-driven upper gastrointestinal cancer. Dig. Surg. 29, 251\u2013260 (2012).","journal-title":"Dig. Surg."},{"key":"531_CR135","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-018-0520-y","volume":"10","author":"PC Galipeau","year":"2018","unstructured":"Galipeau, P. C. et al. NSAID use and somatic exomic mutations in Barrett\u2019s esophagus. Genome Med. 10, 17 (2018).","journal-title":"Genome Med."},{"key":"531_CR136","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1003553","volume":"9","author":"RL Kostadinov","year":"2013","unstructured":"Kostadinov, R. L. et al. NSAIDs modulate clonal evolution in Barrett\u2019s esophagus. PLoS Genet. 9, e1003553 (2013).","journal-title":"PLoS Genet."},{"key":"531_CR137","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1093\/jnci\/djr203","volume":"103","author":"S Bhat","year":"2011","unstructured":"Bhat, S. et al. Risk of malignant progression in Barrett\u2019s esophagus patients: results from a large population-based study. J. Natl Cancer Inst. 103, 1049\u20131057 (2011).","journal-title":"J. Natl Cancer Inst."},{"key":"531_CR138","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1111\/his.13462","volume":"72","author":"MJ van der Wel","year":"2018","unstructured":"van der Wel, M. J. et al. Improved diagnostic stratification of digitised Barrett\u2019s oesophagus biopsies by p53 immunohistochemical staining. Histopathology 72, 1015\u20131023 (2018).","journal-title":"Histopathology"},{"key":"531_CR139","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/his.12956","volume":"69","author":"PV Kaye","year":"2016","unstructured":"Kaye, P. V. et al. Dysplasia in Barrett\u2019s oesophagus: p53 immunostaining is more reproducible than haematoxylin and eosin diagnosis and improves overall reliability, while grading is poorly reproducible. Histopathology 69, 431\u2013440 (2016). In this study, p53 IHC is reported as having increased reliability and inter-observer reliability in the diagnosis of dysplasia but showing poor results in discrimination between LGD and HGD.","journal-title":"Histopathology"},{"key":"531_CR140","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1053\/j.gastro.2011.01.031","volume":"140","author":"SJ Spechler","year":"2011","unstructured":"Spechler, S. J. et al. American Gastroenterological Association technical review on the management of Barrett\u2019s esophagus. Gastroenterology 140, e18\u2013e52 (2011).","journal-title":"Gastroenterology"},{"key":"531_CR141","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1053\/j.gastro.2012.01.013","volume":"142","author":"S Varghese","year":"2012","unstructured":"Varghese, S., Lao-Sirieix, P. & Fitzgerald, R. C. Identification and clinical implementation of biomarkers for Barrett\u2019s esophagus. Gastroenterology 142, 435\u2013441.e2 (2012).","journal-title":"Gastroenterology"},{"key":"531_CR142","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1053\/j.gastro.2018.03.047","volume":"155","author":"MD Stachler","year":"2018","unstructured":"Stachler, M. D. et al. Detection of mutations in Barrett\u2019s esophagus before progression to high-grade dysplasia or adenocarcinoma. Gastroenterology 155, 156\u2013167 (2018).","journal-title":"Gastroenterology"},{"key":"531_CR143","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1053\/j.gastro.2012.06.041","volume":"143","author":"EL Bird-Lieberman","year":"2012","unstructured":"Bird-Lieberman, E. L. et al. Population-based study reveals new risk-stratification biomarker panel for Barrett\u2019s esophagus. Gastroenterology 143, 927\u2013935.e3 (2012).","journal-title":"Gastroenterology"},{"key":"531_CR144","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1136\/gutjnl-2012-303594","volume":"62","author":"F Kastelein","year":"2013","unstructured":"Kastelein, F. et al. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett\u2019s oesophagus. Gut 62, 1676\u20131683 (2013). This paper shows that aberrant p53 IHC staining is associated with an increased risk of neoplastic progression in patients with Barrett oesophagus and increased positive predictive value for neoplastic progression from 15% with histological diagnosis of LGD alone to 33% with LGD and concurrent aberrant p53 expression.","journal-title":"Gut"},{"key":"531_CR145","doi-asserted-by":"publisher","first-page":"102765","DOI":"10.1016\/j.ebiom.2020.102765","volume":"56","author":"AV Hadjinicolaou","year":"2020","unstructured":"Hadjinicolaou, A. V. et al. Aneuploidy in targeted endoscopic biopsies outperforms other tissue biomarkers in the prediction of histologic progression of Barrett\u2019s oesophagus: a multi-centre prospective cohort study. EBioMedicine 56, 102765 (2020).","journal-title":"EBioMedicine"},{"key":"531_CR146","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1053\/j.gastro.2019.09.051","volume":"158","author":"P Sharma","year":"2020","unstructured":"Sharma, P., Shaheen, N. J., Katzka, D. & Bergman, J. AGA Clinical Practice Update on Endoscopic Treatment of Barrett\u2019s Esophagus with Dysplasia and\/or Early Cancer: Expert Review. Gastroenterology 158, 760\u2013769 (2020).","journal-title":"Gastroenterology"},{"key":"531_CR147","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1038\/ajg.2015.260","volume":"110","author":"S van Olphen","year":"2015","unstructured":"van Olphen, S. et al. SOX2 as a novel marker to predict neoplastic progression in Barrett\u2019s esophagus. Am. J. Gastroenterol. 110, 1420\u20131428 (2015).","journal-title":"Am. J. Gastroenterol."},{"key":"531_CR148","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/1097-0142(19950115)75:2<423::AID-CNCR2820750202>3.0.CO;2-5","volume":"75","author":"MK Hong","year":"1995","unstructured":"Hong, M. K. et al. Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett\u2019s esophagus. Cancer 75, 423\u2013429 (1995).","journal-title":"Cancer"},{"key":"531_CR149","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1038\/ajg.2009.437","volume":"104","author":"M Sikkema","year":"2009","unstructured":"Sikkema, M. et al. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett\u2019s esophagus: a case-control study. Am. J. Gastroenterol. 104, 2673\u20132680 (2009).","journal-title":"Am. J. Gastroenterol."},{"key":"531_CR150","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1093\/ajcp\/aqaa004","volume":"153","author":"H Yousaf","year":"2020","unstructured":"Yousaf, H. et al. Surface Ki-67 expression improves reproducibility of dysplasia diagnosis in Barrett\u2019s esophagus. Am. J. Clin. Pathol. 153, 695\u2013704 (2020).","journal-title":"Am. J. Clin. Pathol."},{"key":"531_CR151","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/bjs.10484","volume":"104","author":"K Altaf","year":"2017","unstructured":"Altaf, K., Xiong, J. J., la Iglesia, D., Hickey, L. & Kaul, A. Meta-analysis of biomarkers predicting risk of malignant progression in Barrett\u2019s oesophagus. Br. J. Surg. 104, 493\u2013502 (2017).","journal-title":"Br. J. Surg."},{"key":"531_CR152","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s10620-015-3884-5","volume":"61","author":"JM Findlay","year":"2016","unstructured":"Findlay, J. M., Middleton, M. R. & Tomlinson, I. Genetic biomarkers of Barrett\u2019s esophagus susceptibility and progression to dysplasia and cancer: a systematic review and meta-analysis. Dig. Dis. Sci. 61, 25\u201338 (2016).","journal-title":"Dig. Dis. Sci."},{"key":"531_CR153","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1136\/gutjnl-2017-313815","volume":"67","author":"WT Choi","year":"2017","unstructured":"Choi, W. T. et al. Diagnosis and risk stratification of Barrett\u2019s dysplasia by flow cytometric DNA analysis of paraffin-embedded tissue. Gut 67, 1229\u20131238 (2017).","journal-title":"Gut"},{"key":"531_CR154","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1136\/gutjnl-2015-309642","volume":"65","author":"MR Timmer","year":"2016","unstructured":"Timmer, M. R. et al. Derivation of genetic biomarkers for cancer risk stratification in Barrett\u2019s oesophagus: a prospective cohort study. Gut 65, 1602\u20131610 (2016).","journal-title":"Gut"},{"key":"531_CR155","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0231419","volume":"15","author":"SJM Hoefnagel","year":"2020","unstructured":"Hoefnagel, S. J. M. et al. A genomic biomarker-based model for cancer risk stratification of non-dysplastic Barrett\u2019s esophagus patients after extended follow up; results from Dutch surveillance cohorts. PLoS ONE 15, e0231419 (2020).","journal-title":"PLoS ONE"},{"key":"531_CR156","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1111\/j.1572-0241.2001.05261.x","volume":"96","author":"PS Rabinovitch","year":"2001","unstructured":"Rabinovitch, P. S., Longton, G., Blount, P. L., Levine, D. S. & Reid, B. J. Predictors of progression in Barrett\u2019s esophagus III: baseline flow cytometric variables. Am. J. Gastroenterol. 96, 3071\u20133083 (2001).","journal-title":"Am. J. Gastroenterol."},{"key":"531_CR157","first-page":"1669","volume":"95","author":"BJ Reid","year":"2000","unstructured":"Reid, B. J., Levine, D. S., Longton, G., Blount, P. L. & Rabinovitch, P. S. Predictors of progression to cancer in Barrett\u2019s esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am. J. Gastroenterol. 95, 1669\u20131676 (2000).","journal-title":"Am. J. Gastroenterol."},{"key":"531_CR158","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/nrc.2017.102","volume":"18","author":"K Curtius","year":"2018","unstructured":"Curtius, K., Wright, N. A. & Graham, T. A. An evolutionary perspective on field cancerization. Nat. Rev. Cancer 18, 19\u201332 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"531_CR159","doi-asserted-by":"publisher","first-page":"177","DOI":"10.5858\/2005-129-177-DOPRFB","volume":"129","author":"ER Tschanz","year":"2005","unstructured":"Tschanz, E. R. Do 40% of patients resected for Barrett esophagus with high-grade dysplasia have unsuspected adenocarcinoma? Arch. Pathol. Lab. Med. 129, 177\u2013180 (2005).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"531_CR160","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1053\/j.gastro.2013.05.004","volume":"145","author":"DA Corley","year":"2013","unstructured":"Corley, D. A. et al. Impact of endoscopic surveillance on mortality from Barrett\u2019s esophagus-associated esophageal adenocarcinomas. Gastroenterology 145, 312\u2013319.e1 (2013).","journal-title":"Gastroenterology"},{"key":"531_CR161","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.cgh.2009.10.010","volume":"8","author":"M Sikkema","year":"2010","unstructured":"Sikkema, M., de Jonge, P. J., Steyerberg, E. W. & Kuipers, E. J. Risk of esophageal adenocarcinoma and mortality in patients with Barrett\u2019s esophagus: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 8, 235\u2013244 (2010). quiz e232.","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"531_CR162","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02621-x","volume":"9","author":"P Martinez","year":"2018","unstructured":"Martinez, P. et al. Evolution of Barrett\u2019s esophagus through space and time at single-crypt and whole-biopsy levels. Nat. Commun. 9, 794 (2018).","journal-title":"Nat. Commun."},{"key":"531_CR163","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S2468-1253(16)30118-2","volume":"2","author":"CS Ross-Innes","year":"2017","unstructured":"Ross-Innes, C. S. et al. Risk stratification of Barrett\u2019s oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study. Lancet Gastroenterol. Hepatol. 2, 23\u201331 (2017).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"531_CR164","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aao5848","volume":"10","author":"HR Moinova","year":"2018","unstructured":"Moinova, H. R. et al. Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett\u2019s esophagus. Sci. Transl. Med. 10, eaao5848 (2018).","journal-title":"Sci. Transl. Med."},{"key":"531_CR165","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.1158\/0008-5472.CAN-09-0028","volume":"69","author":"Z Jin","year":"2009","unstructured":"Jin, Z. et al. A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett\u2019s esophagus. Cancer Res. 69, 4112\u20134115 (2009).","journal-title":"Cancer Res."},{"key":"531_CR166","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1158\/1078-0432.CCR-12-2880","volume":"19","author":"MA Alvi","year":"2013","unstructured":"Alvi, M. A. et al. DNA methylation as an adjunct to histopathology to detect prevalent, inconspicuous dysplasia and early-stage neoplasia in Barrett\u2019s esophagus. Clin. Cancer Res. 19, 878\u2013888 (2013).","journal-title":"Clin. Cancer Res."},{"key":"531_CR167","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.4161\/epi.6.12.18199","volume":"6","author":"AM Kaz","year":"2011","unstructured":"Kaz, A. M. et al. DNA methylation profiling in Barrett\u2019s esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclasses. Epigenetics 6, 1403\u20131412 (2011).","journal-title":"Epigenetics"},{"key":"531_CR168","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1038\/s41395-018-0107-7","volume":"113","author":"PG Iyer","year":"2018","unstructured":"Iyer, P. G. et al. Highly discriminant methylated DNA markers for the non-endoscopic detection of Barrett\u2019s esophagus. Am. J. Gastroenterol. 113, 1156\u20131166 (2018).","journal-title":"Am. J. Gastroenterol."},{"key":"531_CR169","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1158\/1078-0432.CCR-18-3696","volume":"25","author":"Z Wang","year":"2019","unstructured":"Wang, Z. et al. Methylation biomarker panel performance in esophacap cytology samples for diagnosing Barrett\u2019s esophagus: a prospective validation study. Clin. Cancer Res. 25, 2127\u20132135 (2019).","journal-title":"Clin. Cancer Res."},{"key":"531_CR170","doi-asserted-by":"publisher","first-page":"3414","DOI":"10.1158\/0008-5472.CAN-03-3249","volume":"64","author":"CC Maley","year":"2004","unstructured":"Maley, C. C. et al. Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett\u2019s esophagus. Cancer Res. 64, 3414\u20133427 (2004).","journal-title":"Cancer Res."}],"container-title":["Nature Reviews Gastroenterology &amp; Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41575-021-00531-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-021-00531-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-021-00531-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T01:11:05Z","timestamp":1675818665000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41575-021-00531-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,2]]},"references-count":170,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["531"],"URL":"https:\/\/doi.org\/10.1038\/s41575-021-00531-4","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,2]]},"assertion":[{"value":"24 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}